Comparative Pharmacology
Head-to-head clinical analysis: ONGLYZA versus SITAGLIPTIN PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ONGLYZA versus SITAGLIPTIN PHOSPHATE.
ONGLYZA vs SITAGLIPTIN PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) to enhance glucose-dependent insulin secretion and suppress glucagon release.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that slows the inactivation of incretin hormones (GLP-1 and GIP), thereby increasing their levels and prolonging their action. This enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner.
2.5 mg or 5 mg orally once daily
100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12.4 hours for saxagliptin. The half-life of its active metabolite is about 2.1 hours. The pharmacologically relevant half-life supports once-daily dosing.
Terminal elimination half-life: 12.4 hours (range 8–14 hours). Clinically, supports once-daily dosing with gradual onset of DPP-4 inhibition.
Approximately 75% of the administered dose is excreted in urine, with about 21% recovered as parent drug, and the remainder as metabolites. Fecal excretion accounts for about 22% of the dose, primarily as parent drug and metabolites.
Renal excretion: ~87% (as unchanged drug in urine); biliary/fecal: ~13% (as metabolites and unchanged drug).
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor